THE GENERICS DICTIONARY VOLUME 30 NO 4
D E C E M B E R 20 2 5 / JA N UA R Y 20 2 6
NEW LAUNCH
Midazolam 5 mg / 0,1 mL
First to market Midazolam Nasal Spray in South Africa1
Seize Control, Break the Stigma
3
2
MIRANOST is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.4
EMPOWERING LIVES BEYOND EPILEPSY. S5 Reg. No. 58/2.5/0059. Miranost. Each single-dose nasal spray unit contains midazolam 5 mg / 0,1 mL, ethanol (alcohol) 7,60 % w/v. For full prescribing information, refer to the Professional Information approved by the medicines regulatory authority. References: 1. Data on file CIPLA MEDPRO, 2025. 2. Detyniecki, K. et al. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters—a randomized, double-blind, placebo-controlled trial. Epilepsia 60, 1797–1808 (2019). 3. Meng, T. C. et al. Psychosocial outcomes of repeated treatment of seizure clusters with midazolam nasal spray: Results of a phase 3, open-label extension trial. Epilepsy and Behavior 138, (2023). 4. MIRANOST Approved Professional Information. (Cipla, February 2024). Manufactured by: CIPLA MEDPRO (PTY) LTD. Co. Reg. No. 1995/004182/07. Building 2, Junxion Park, 10 Elephant Lane, Century City 7441. Website: www.cipla.co.za Customer Care: 080 222 6662.[1790984610e]